New cholesterol drug’s high price may not be worth it: Study

From Newsmax Despite being slashed by half in recent months, the price tag for advanced cholesterol-fighting drugs is still too high to make them cost-effective, a new analysis has concluded. In March, the manufacturer of alirocumab (Praluent) announced that it…